Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer

被引：0
|
作者：
Fessler, Beate
机构：
来源：
BREAST CARE | 2023年 / 18卷 / 02期
关键词：
D O I：
10.1159/000530539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [22] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [23] Provider perceptions of DESTINY-Breast04, HER2-low directed treatment, and interstitial lung disease
    Leon, Brooke
    Bone, Robert
    Jeune-Smith, Yolaine
    Feinberg, Bruce
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Xu, Binghe
    Wang, Xiaojia
    Gil-Gil, Miguel
    Li, Wei
    Pierga, Jean-Yves
    Im, Seock-Ah
    Moore, Halle C. F.
    Rugo, Hope S.
    Yerushalmi, Rinat
    Zagouri, Flora
    Gombos, Andrea
    Kim, Sung-Bae
    Liu, Qiang
    Luo, Ting
    Saura, Cristina
    Schmid, Peter
    Sun, Tao
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Vitazka, Patrik
    Meinhardt, Gerold
    Harbeck, Nadia
    Cameron, David A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01): : 9 - 20
  • [25] Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
    Poumeaud, F.
    Morisseau, M.
    Cabel, L.
    Goncalves, A.
    Rivier, C.
    Tredan, O.
    Volant, E.
    Frenel, J. -s.
    Ladoire, S.
    Jacot, W.
    Jamelot, M.
    Foka Tichoue, H.
    Patsouris, A.
    Teixeira, L.
    Bidard, F. -c.
    Loirat, D.
    Brunet, M.
    Levy, C.
    Bailleux, C.
    Cabarrou, B.
    Deleuze, A.
    Uwer, L.
    Deluche, E.
    Grellety, T.
    Franchet, C.
    Fiteni, F.
    Bischoff, H.
    Vion, R.
    Pagliuca, M.
    Verret, B.
    Becourt, S.
    Reverdy, T.
    de Nonneville, A.
    Dalenc, F.
    BRITISH JOURNAL OF CANCER, 2024, 131 (04) : 702 - 708
  • [26] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [27] HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer
    Zou, Y.
    Deng, X.
    Xie, J.
    Zeng, Y.
    Jing, B.
    Fu, J.
    Jiang, Y.
    Tang, H.
    Liu, P.
    Xie, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S1418 - S1418
  • [28] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [29] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
    Modi, S.
    Jacot, W.
    Iwata, H.
    Park, Y. H.
    Vidal Losada, M. J.
    Li, W.
    Tsurutani, J.
    Zaman, K.
    Ueno, N. T.
    Prat, A.
    Papazisis, K.
    Rugo, H. S.
    Harbeck, N.
    Im, S-A.
    De Laurentiis, M.
    Orbegoso, C. M. A.
    Yung, L.
    Cheng, F-C.
    Cheng, Y.
    Cameron, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S334 - S335
  • [30] Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer
    Onishi, Mai
    Shimoi, Tatsunori
    Kitadai, Rui
    Tokura, Momoko
    Yazaki, Shu
    Sumiyoshi-Okuma, Hitomi
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Syosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1423 - S1423
12345